Everything below concerns CAS Registry Number. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The original gun-type plutonium weapon, code-named "Thin Man", had to be abandoned as a result—the increased number of spontaneous neutrons meant that nuclear pre-detonation (fizzle) was likely. The entire plutonium weapon design effort at Los Alamos was soon changed to the more complicated implosion device, code-named "Fat Man". In an implosion bomb, plutonium is compressed to high density with explosive lenses—a technically more daunting task than the simple gun-type bomb, but necessary for a plutonium bomb. Uranium, by contrast, can be used with either method. Construction of the Hanford B Reactor, the first industrial-sized nuclear reactor for the purposes of material production, was completed in March 1945. B Reactor produced the fissile material for the plutonium weapons used during World War II. B, D and F were the initial reactors built at Hanford, and six additional plutonium-producing reactors were built later at the site. By the end of January 1945, the highly purified plutonium underwent further concentration in the completed chemical isolation building, where remaining impurities were removed successfully. Los Alamos received its first plutonium from Hanford on February 2. While it was still by no means clear that enough plutonium could be produced for use in bombs by the war's end, Hanford was by early 1945 in operation. Only two years had passed since Col. Franklin Matthias first set up his temporary headquarters on the banks of the Columbia River.
By the late 20th century, new fields like genomics and proteomics were reversing this trend, with organismal biologists using molecular techniques, and molecular and cell biologists investigating the interplay between genes and the environment, as well as the genetics of natural populations of organisms.
=== Neurological safety === Reviews found no evidence that low doses of aspartame had neurotoxic effects. A 2019 policy statement by the American Academy of Pediatrics concluded that there were no safety concerns about aspartame in fetal or childhood development or as a factor in attention deficit hyperactivity disorder.
By taking command in person, Buller had allowed the overall direction of the war to drift. Because of concerns about his performance and negative reports from the field, he was replaced as Commander in Chief by Lord Roberts. Roberts assembled a new team for headquarters staff from far and wide: Lord Kitchener (Chief of Staff) from the Sudan; Frederick Russell Burnham (Chief of Scouts), the American scout, from the Klondike; George Henderson from the Staff College; Neville Bowles Chamberlain from Afghanistan; and William Nicholson (Military Secretary) from Calcutta. Like Buller, Roberts first intended to attack directly along the Cape Town–Pretoria railway but, again like Buller, was forced to relieve the beleaguered garrisons. Leaving Buller in command in Natal, Roberts massed his main force near the Orange River and along the Western Railway behind Methuen's force at the Modder River and prepared to make a wide outflanking move to relieve Kimberley. Except in Natal, the war had stagnated. Other than a single attempt to storm Ladysmith, the Boers made no attempt to capture the besieged towns. In the Cape Midlands, the Boers did not exploit the British defeat at Stormberg and were prevented from capturing the railway junction at Colesberg. In the dry summer, the grazing on the veld became parched, weakening the Boers' horses and draught oxen, and many Boer families joined their menfolk in the siege lines and laagers (encampments), fatally encumbering Cronjé's army.
Sources: en.wikipedia.org
== See also == Androgenic hair Bearded lady Ferriman-Gallwey score Hair removal Hypertrichosis Laser hair removal Petrus Gonsalvus Polyendocrine metabolic ovarian syndrome (PMOS) Pubic hair Social model of disability Trichophilia
Hylomorphism is a philosophical doctrine developed by the Ancient Greek philosopher Aristotle, which conceives every physical entity or being (ousia) as a compound of matter (potency) and substantial form (act), with the generic form as immanently real within the individual. The word is a 19th-century term formed from the Greek words ὕλη (hyle: "wood, matter") and μορφή (morphē: "form"). Hylomorphic theories of physical entities have been undergoing a revival in contemporary philosophy, especially since the 2000s.
=== Food sources === Hydra, as a carnivorous cnidarian, mainly feeds on small aquatic invertebrates. Hydra can also eat worms, young insects, larval mollusks, bluegill larvae, tiny crustaceans (e.g., Daphnia, Cyclops, ostracods, cladocerans, and copepods), and algaes (e.g., Cocconeis placentula, Cyclotella meneghineana, and Navicula zanoni). Some species of Hydra exist in a mutual relationship with various types of unicellular algae. The algae are protected from predators by Hydra; in return, photosynthetic products from the algae are beneficial as a food source to Hydra and even help to maintain the Hydra microbiome. There is an entire clade of "green hydra" where the species can stably maintain a population of Chlorella internally, with the main representative being Hydra viridissima. There are at least 4 species in this clade. The other species are called "brown hydra". There exists an immature symbiotic relationship between some strains of Hydra vulgaris and Chlorococcum.
== Further reading == Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, et al. (March 2021). "A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis". The Journal of Dermatology. 48 (3): 279–288. doi:10.1111/1346-8138.15668. PMC 7986147. PMID 33410265.
=== Middle Eastern countries === As of March 2026, Nando's has five restaurants in Bahrain; two in Manama and one each in Amwaj Islands, Isa Town and Saar. In Qatar, Nando's has been established since 2001, with the first restaurant located on Salwa Road. As of October 2022, Nando's has eight branches in Qatar, seven of which are located in Doha while one is in Al Wakrah. In Saudi Arabia, Nando's opened its first restaurant within the country on 12 December 2016 in Riyadh, and opened its first branch in Jeddah on 8 December 2018 As of March 2026, Nando's has nine branches in Saudi Arabia; three in Riyadh, three in Jeddah; and one each in Dhahran, Dammam and Khobar. Nando's opened its first restaurant within the United Arab Emirates in Dubai (along Sheikh Zayed Road) in 2002 and opened its first branch in Abu Dhabi in 2014. As of August 2021, Nando's has 19 branches in the UAE; 13 in Dubai, three in Abu Dhabi and one each in Sharjah, Al Ain and Ras Al Khaimah. As a former market, Israel was home to a successful Nando's franchise network throughout the 1990s and 2000s, with the Israeli operation involving the Brozin brothers alongside the international Nando's business. The first Israeli branch opened in Herzliya in 1993, and by 1996 there were branches in Tel Aviv, Herzliya and Haifa, with plans for further expansion. By March 2004, the network had grown to 15 restaurants. In December 2005, Nando's Israel was acquired by Israeli businessman Yuval Doron's Eddy Global Holdings. Kenny Brozin remained chief executive of the Israeli operation until June 2006.
Sources: en.wikipedia.org
=== Types === Inorganic compounds: potassium alum, aluminium hydroxide, aluminium phosphate, calcium phosphate hydroxide Oils: paraffin oil, propolis (only in preclinical studies). Adjuvant 65 (based on peanut oil) was tested in influenza vaccines in the 1970s, but was never released commercially. Freund's incomplete adjuvant is a water-in-oil emulsion, a classical adjuvant. Water-in-oils are generally too reactogenic to be used on humans, however. Squalene is a natural oil made by human bodies. MF59 is a oil-in-water emulsion based on squalene. Bacterial products: killed bacteria of the species Bordetella pertussis, Mycobacterium bovis, toxoids. MPL (Monophosphorylated lipid A) is a modified form of a bacterial lipid A protein that is used in several vaccines. Plant saponins from Quillaia (soap bark tree), soybean and Polygala senega Cytokines: IL-1, IL-2, IL-12 CpG oligonucleotides Combinations: Freund's complete adjuvant (incomplete + dead Mycobacterium), AS01 (combining MPL and Quillaia saponins), Matrix-M (combining Quillaia saponins and two types of fat) Small molecules: TLR7/8 agonists (imidazoquinolines, imidazopyrimidines) Physical methods: radiofrequency heating (only tested in mice), microneedles (only tested in mice)
=== Evidence === At trial, the prosecution presented evidence from parents, clinicians and expert witnesses. The mother of Baby E testified that she had heard her son cry and found blood around his mouth while Letby was present; Letby attributed the blood to a nasogastric tube. Baby E died later that day. Letby subsequently sent a sympathy card to the family, photographs of which were later found on her phone. The court also heard that she had been advised more than once not to enter a room where bereaved parents were grieving. Prosecutors cited text messages sent by Letby to colleagues, which they said showed inappropriate interest in clinical events. Messages included offers to take additional intensive‑care shifts shortly after deaths or collapses, expressions of frustration when not allocated to intensive‑care rooms, and comments about fate following a series of deaths. The court also heard that Letby had searched for the families of several infants on Facebook, sometimes on anniversaries or significant dates. She told the jury this reflected general curiosity and frequent phone use. Consultants testified that they believed suspicious incidents began after Letby qualified to work in intensive care in 2015 and that the pattern of collapses shifted after she was moved from night to day shifts in 2016. One consultant said he had found Letby standing over a deteriorating infant in February 2016 and believed she had not intervened promptly; the infant survived.
(WINNER) The contestant won the whole competition. (WIN) The contestant won the Haunted Heat (HIGH) The contestant had one of the best dishes in the Haunted Heat. (IN) The contestant performed well enough to move on to the next week. ‡ The judges recognized this contestant for having the best dish in the Bake for Your Life challenge. (LOW) The contestant had one of the bottom dishes but was not eliminated. (OUT) The contestant was eliminated for worst dish.
Coldspring Pilgrim's Pride Cold Spring Brewing Company. Founded in 1874 by German immigrant Michael Sargl, CSBC produces, packages, and distributes soft drinks, beer, malt beverages, energy drinks, and other beverages. In 2012, the Third Street Brewhouse was started and became CSBC's craft beer division. Brynwood Partners, a Connecticut-based private equity firm, bought the company from the Lenore family in August 2017. At the time, the company had roughly 350 employees and annual sales of more than $60 million. Rocori School District Assumption Community Cold Spring Bakery. Started in 1946 by Melvin and Floss Schurman, and originally known as the Home Bakery, the bakery is on Main Street. It distributes its goods across Central Minnesota and is still owned and managed by the Schurman family.
Clinical outcomes include depressed growth, diarrhea, impotence and delayed sexual maturation, alopecia, eye and skin lesions, impaired appetite, altered cognition, impaired immune functions, defects in carbohydrate use, and reproductive teratogenesis. Zinc deficiency depresses immunity, but excessive zinc does also. Despite some concerns, western vegetarians and vegans do not suffer any more from overt zinc deficiency than meat-eaters. Major plant sources of zinc include cooked dried beans, sea vegetables, fortified cereals, soy foods, nuts, peas, and seeds. However, phytates in many whole-grains and fibers may interfere with zinc absorption and marginal zinc intake has poorly understood effects. The zinc chelator phytate, found in seeds and cereal bran, can contribute to zinc malabsorption. Some evidence suggests that more than the US RDA (8 mg/day for adult women; 11 mg/day for adult men) may be needed in those whose diet is high in phytates, such as some vegetarians. The European Food Safety Authority (EFSA) guidelines attempt to compensate for this by recommending higher zinc intake when dietary phytate intake is greater. These considerations must be balanced against the paucity of adequate zinc biomarkers, and the most widely used indicator, plasma zinc, has poor sensitivity and specificity.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.